Skip to main content
main-content

Spondyloarthropathies

Ankylosing spondylitis

04-12-2018 | Ankylosing spondylitis | News

Elevated CRP levels may point to better secukinumab response in AS patients

Ankylosing spondylitis patients with elevated C-reactive protein levels may experience greater benefits from treatment with the interleukin-17A inhibitor secukinumab than those with lower levels of the inflammatory marker, researchers report.

Source:

RMD Open 2018; 4: e000749

Golimumab may reduce uveitis risk in patients with ankylosing spondylitis

Findings from the real-world GO-EASY study suggest that treatment with the tumor necrosis factor inhibitor golimumab is associated with a significant reduction in the risk for acute anterior uveitis among patients with ankylosing spondylitis.

13-11-2018 | Ankylosing spondylitis | Highlight | News

Golimumab may reduce uveitis risk in patients with ankylosing spondylitis

Findings from the real-world GO-EASY study suggest that treatment with the tumor necrosis factor inhibitor golimumab is associated with a significant reduction in the risk for acute anterior uveitis among patients with ankylosing spondylitis.

Source:

J Rheumatol 2018; doi:10.3899/jrheum.180312

03-10-2018 | Ankylosing spondylitis | Article

Influence of HLA-B27 on the ankylosing spondylitis phenotype: Results from the REGISPONSER database

Arévalo M et al. Arthritis Res Ther 2018; 20: 221. doi: 10.1186/s13075-018-1724-7

Further investigation of filgotinib warranted in ankylosing spondylitis patients

Findings from the phase II TORTUGA trial suggest that treatment with the JAK1 inhibitor filgotinib may be beneficial for patients with ankylosing spondylitis who have not responded to treatment with nonsteroidal anti-inflammatory drugs.

26-10-2018 | Ankylosing spondylitis | ACR/ARHP 2018 | News

Further evidence for the benefits of ixekizumab in ankylosing spondylitis

Findings from the COAST-W trial provide support for the IL-17A inhibitor ixekizumab as a treatment option for patients with ankylosing spondylitis and a previous inadequate response or intolerance to TNF inhibitor treatment.

Source:

ACR/ARHP Annual Meeting; Chicago, Illinois, USA: 19–24 October 2018

26-10-2018 | Ankylosing spondylitis | News | Article

Further investigation of filgotinib warranted in ankylosing spondylitis patients

Findings from the phase II TORTUGA trial suggest that treatment with the JAK1 inhibitor filgotinib may be beneficial for patients with ankylosing spondylitis who have not responded to treatment with nonsteroidal anti-inflammatory drugs.

Source:

Lancet 2018; doi:10.1016/S0140-6736(18)32463-2
Lancet 2018; doi:10.1016/S0140-6736(18)32600-X

24-10-2018 | Ankylosing spondylitis | ACR/ARHP 2018 | News

News in brief

Genetic risk scores may aid ankylosing spondylitis detection

Researchers have developed two polygenic risk scores to identify individuals at high risk for ankylosing spondylitis.

24-10-2018 | Cardiovascular disease | ACR/ARHP 2018 | Video

Looking to collaborative models of care to improve primary prevention of CVD in patients with inflammatory arthritis

Lihi Eder describes a new model of care based on collaboration between cardiologists and rheumatologists to better manage cardiovascular risk factors in patients with inflammatory arthritis (5:56).

COAST-V results support ixekizumab for the treatment of ankylosing spondylitis

Phase III trial results indicate that ixekizumab may be a promising treatment option for biologic-naïve patients with ankylosing spondylitis and an inadequate response or intolerance to nonsteroidal anti-inflammatory drugs.

23-10-2018 | Ankylosing spondylitis | ACR/ARHP 2018 | News

COAST-V results support ixekizumab for the treatment of ankylosing spondylitis

Phase III trial results indicate that ixekizumab may be a promising treatment option for biologic-naïve patients with ankylosing spondylitis and an inadequate response or intolerance to nonsteroidal anti-inflammatory drugs.

Source:

Lancet 2018; doi:10.1016/S0140-6736(18)31946-9
Lancet 2018; doi:10.1016/S0140-6736(18)32340-7
ACR/ARHP Annual Meeting; Chicago, Illinois, USA: 19–24 October 2018

21-08-2018 | DMARDs | Article

The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis: Executive summary

Holroyd CR et al. Rheumatology (Oxford) 2018: key207. doi: 10.1093/rheumatology/key207

21-08-2018 | DMARDs | Article

The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis

Holroyd CR et al. Rheumatology (Oxford) 2018: key207. doi: 10.1093/rheumatology/key208

21-08-2018 | Axial spondyloarthritis | Review | Article

Radiologic approach to axial spondyloarthritis: Where are we now and where are we heading?

Kucybała I, Urbanik A, Wojciechowski W. Rheumatol Int 2018. doi: 10.1007/s00296-018-4130-1

20-08-2018 | Nursing | Review | Article

Nurses’ roles in the management of chronic inflammatory arthritis: A systematic review

Vivienne L, Michael S. Rheumatol Int 2018. doi: 10.1007/s00296-018-4135-9

07-09-2018 | Treatment | Feature | Article

At a glance: Common scores used in rheumatology

A quick-reference guide to the scores that are commonly used in clinical trials and daily rheumatology practice.

11-08-2018 | Spondyloarthropathies | Review | Article

Ultrasound of sacroiliac joints in spondyloarthritis: A systematic review

Gutierrez M et al. Rheumatol Int 2018. doi: 10.1007/s00296-018-4126-x

image credits